WO2017159554A1 - 還元型グルタチオンの結晶及びその製造方法 - Google Patents
還元型グルタチオンの結晶及びその製造方法 Download PDFInfo
- Publication number
- WO2017159554A1 WO2017159554A1 PCT/JP2017/009655 JP2017009655W WO2017159554A1 WO 2017159554 A1 WO2017159554 A1 WO 2017159554A1 JP 2017009655 W JP2017009655 W JP 2017009655W WO 2017159554 A1 WO2017159554 A1 WO 2017159554A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reduced glutathione
- crystal
- crystals
- aqueous solution
- less
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 224
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 185
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 158
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 229960003180 glutathione Drugs 0.000 title abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 23
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000843 powder Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 150000001298 alcohols Chemical class 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 230000000704 physical effect Effects 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- -1 Most preferably Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to a crystal of reduced glutathione excellent in powder physical properties and a method for producing the same.
- Reduced glutathione ( ⁇ -L-glutamyl-L-cysteinyl-L-glycine) is a reducing compound widely present in living organisms and is known to have a detoxifying action in the liver. For this reason, reduced glutathione is widely used as products, raw materials, or intermediates such as pharmaceuticals, health foods, and cosmetics.
- Two types of crystal polymorphs, ⁇ -crystal and ⁇ -crystal, are known for reduced glutathione crystals (Non-patent Document 1), but the ⁇ -crystal is generally used as a product because of its physical properties. .
- ⁇ -crystals of reduced glutathione tend to become needle-like or elongated columnar crystals because of slow crystal growth in directions other than the major axis (longitudinal) direction. Because of this property, there is a problem that the specific volume increases and the fluidity of the powder deteriorates as a result of an increase in the ratio of the length and width of the crystal. In order to improve the powder physical properties, it is necessary to grow the crystal not only in the vertical direction but also in the horizontal direction and the height direction.
- Patent Document 1 describes the improvement of the powder physical properties of reduced glutathione, and after adding crystals of reduced glutathione as seed crystals to an aqueous solution in which reduced glutathione is dissolved, the aqueous solution is stirred to Discloses a method for precipitating reduced glutathione.
- Patent Document 1 is a method in which supersaturation is rapidly broken by adding seed crystals to a high-concentrated reduced glutathione-containing aqueous solution. There was a problem that was insufficient.
- an object of the present invention is to provide reduced glutathione crystals excellent in fluidity and grindability and a method for producing the same.
- the present invention relates to the following (1) to (10).
- FIG. 1 shows the change in the crude specific volume over time when the crystals of reduced glutathione obtained in Example 3 and Comparative Example were pulverized.
- the vertical axis represents the crude specific volume (mL / g), and the horizontal axis represents the grinding time (minutes).
- the white diamond represents the result of the comparative example crystal
- the black circle represents the result of the crystal of Example 3.
- FIG. 2 shows a schematic diagram of a reduced glutathione crystal of the present invention.
- the longest axis is referred to as the vertical axis
- the axis perpendicular to the vertical axis is referred to as the horizontal axis (FIG. 2).
- the length of the crystal in the vertical axis direction, the major axis of the cross section of the horizontal axis, and the minor axis of the cross section of the horizontal axis are referred to as “crystal length”, “crystal width”, and “crystal thickness”, respectively.
- the respective averages are referred to as “average length”, “average width”, and “average thickness” (see FIG. 2).
- the average length, average width, and average thickness are also referred to as “L”, “W”, and “T”, respectively.
- L, W and T can be measured by the method described in the analysis examples described later.
- the length of the crystal and the width of the crystal can be measured, for example, using an optical microscope [DIGITAL MICROSCOPE VHX-900 (KEYENCE)] at a measurement magnification of 300 to 600 times.
- the crystal length and the crystal width are measured for 200 crystals, and the average length L, the average width W, and the ratio L / W between the average length L and the average width W are calculated (FIG. 2, left diagram).
- the thickness of the crystal can be measured, for example, using a scanning electron microscope [JSM-6510 type (manufactured by JEOL Ltd.)] at a measurement magnification of 250 to 1000 times. For example, for 50 crystals, a crystal whose vertical axis is perpendicular to the field of view of the scanning electron microscope is selected, the crystal thickness is measured (FIG. 2, right diagram), and the average thickness T is measured. The sample is fixed to an aluminum sample stage with carbon double-sided tape.
- JSM-6510 type manufactured by JEOL Ltd.
- the crystals of reduced glutathione of the present invention have an average crystal thickness (T) of 10 ⁇ m or more, preferably 11 ⁇ m or more, more preferably 12 ⁇ m or more, and most preferably 13 ⁇ m or more.
- a crystal having a large crystal thickness is excellent in grindability, so that the reduced glutathione crystal preferably has a large crystal thickness, but the upper limit of the average thickness of the reduced glutathione crystal of the present invention is usually 40 ⁇ m or less, preferably 35 ⁇ m or less, more preferably 30 ⁇ m or less, and most preferably 25 ⁇ m or less.
- the ratio L / W of the average length L to the average width W is preferably 6.0 or less, more preferably 5.5 or less, still more preferably 5.0 or less, most preferably 4.5 or less.
- L / W is preferably small for reduced glutathione crystals, but the lower limit of L / W is usually 1.0 or more, preferably 1.1 or more, more preferably 1.2 or more, most preferably Preferably, 1.5 or more can be mentioned.
- Examples of the reduced glutathione crystals of the present invention include reduced glutathione crystals having an average crystal thickness (T) of 10 ⁇ m or more and a crystal L / W of preferably 6.0 or less.
- the reduced glutathione crystal of the present invention has a crude specific volume of preferably 2.5 mL / g or less, more preferably 2.3 mL / g or less, still more preferably 2.2 mL / g or less, and most preferably 2.0 mL. / G or less.
- the reduced glutathione crystal preferably has a small crude specific volume, but the lower limit of the crude specific volume is usually 1.0 mL / g or more, preferably 1.2 mL / g or more. .
- the coarse specific volume means a value obtained by dividing the volume occupied by the powder when the container is filled with the powder and its mass is measured.
- the crude specific volume can be measured, for example, using a multi-tester MT-1001T type (manufactured by Seishin Enterprise Co., Ltd.) according to the attached manual under the following measurement conditions.
- Examples of the reduced glutathione crystals of the present invention include reduced glutathione crystals having an average crystal thickness (T) of 10 ⁇ m or more and a crude specific volume of preferably 2.5 mL / g or less.
- the reduced glutathione crystals of the present invention have a dense specific volume of preferably 2.0 mL / g or less, more preferably 1.8 mL / g or less, still more preferably 1.6 mL / g or less, and most preferably 1.5 mL. / G or less.
- the reduced glutathione crystal preferably has a small dense specific volume, but the lower limit of the dense specific volume is usually 0.8 mL / g or more, preferably 1.0 mL / g or more. .
- the dense specific volume is a value obtained by dividing the volume occupied by the powder by applying a certain impact to the container after the container is filled with the powder and measuring its mass.
- the dense specific volume can be measured, for example, using a multi-tester MT-1001T type (manufactured by Seishin Enterprise Co., Ltd.) according to the attached manual under the following measurement conditions.
- Tapping speed 1 time / second Tapping frequency: 200 times
- Examples of the reduced glutathione crystals of the present invention include reduced glutathione crystals having an average crystal thickness (T) of 10 ⁇ m or more and a dense specific volume of preferably 2.0 mL / g or less.
- the difference between the crude specific volume and the dense specific volume is preferably 1.2 mL / g or less, more preferably 1.0 mL / g or less.
- the lower limit of the difference between the crude specific volume and the dense specific volume is usually 0.1 mL / g or more, preferably 0.2 mL / g or more.
- the difference between the coarse specific volume and the dense specific volume refers to a positive value when the dense specific volume is subtracted from the coarse specific volume.
- the reduced glutathione crystal of the present invention has an average crystal thickness (T) of 10 ⁇ m or more, and preferably L / W of the crystal of 6.0 or less, and there is a difference between the crude specific volume and the dense specific volume.
- T average crystal thickness
- Preferred examples include reduced glutathione crystals of 1.2 mL / g or less.
- the crystal of reduced glutathione of the present invention has an angle of repose of preferably 50 degrees or less, more preferably 48 degrees or less, still more preferably 47 degrees or less, and most preferably 45 degrees or less.
- the reduced glutathione crystal preferably has a small angle of repose, but the lower limit of the angle of repose is usually 30 degrees or more, preferably 35 degrees or more.
- the angle of repose refers to the angle formed between the generatrix of the cone formed by the powder and the horizontal plane when the powder is gently dropped onto a horizontal surface like a funnel.
- the angle of repose can be measured, for example, using a multitester MT-1001T type (manufactured by Seishin Enterprise Co., Ltd.) according to the attached manual under the following measurement conditions.
- Examples of the reduced glutathione crystals of the present invention include reduced glutathione crystals having an average crystal thickness (T) of 10 ⁇ m or more and an angle of repose of preferably 50 degrees or less.
- the crystal of reduced glutathione of the present invention has a collapse angle of preferably 45 degrees or less, more preferably 43 degrees or less, still more preferably 42 degrees or less, and most preferably 40 degrees or less.
- the difference between the collapse angle and the repose angle is preferably small, but the lower limit value of the collapse angle is usually 30 degrees or more, preferably Can mention 35 degrees or more.
- the decay angle is formed when a constant impact is indirectly applied to a cone formed by powder when the powder is gently dropped on a horizontal surface like a funnel.
- the collapse angle can be measured, for example, using a multi-tester MT-1001T type (manufactured by Seishin Enterprise Co., Ltd.) according to the attached manual under the following measurement conditions.
- Examples of the reduced glutathione crystals of the present invention include reduced glutathione crystals having an average crystal thickness (T) of 10 ⁇ m or more and a collapse angle of preferably 45 degrees or less.
- the crystal of reduced glutathione of the present invention may be a crystalline powder containing crystal polymorphs such as ⁇ crystal and ⁇ crystal, but ⁇ crystal is preferable as the crystal of reduced glutathione.
- the ratio of ⁇ crystal in the total reduced glutathione is usually 95% or more, preferably 97% or more, more preferably 98% or more, further preferably 99% or more, particularly preferably 99.5% or more, Most preferred is a crystalline powder of 99.9% or more.
- the production method of the present invention comprises reducing glutathione crystals in a reduced glutathione-containing aqueous solution, and then adding a supersaturated reduced glutathione-containing aqueous solution to the aqueous solution in a continuous or divided manner.
- the method is characterized in that crystals of reduced glutathione are precipitated and / or grown, and then crystals of reduced glutathione contained in the aqueous solution are collected.
- the reduced glutathione-containing aqueous solution may be produced by any production method such as a fermentation method, an enzyme method, an extraction method from a natural product, or a chemical synthesis method.
- a culture containing reduced glutathione obtained by culturing a microorganism having the ability to produce glutathione International Publication No. 2008/126784
- an aqueous solution containing reduced glutathione obtained by an enzymatic method [Appl. Microbiol. Biotechnol., 66, 233 (2004), Japanese Patent Application Laid-Open No. 60-105499, etc.] and the like can be mentioned.
- More preferred is an aqueous solution of reduced glutathione obtained by the method described in Example 1 of Japanese Patent No. 5243963.
- the reduced glutathione-containing aqueous solution for example, by concentrating the reduced glutathione-containing aqueous solution to a concentration equal to or higher than the saturation solubility, the reduced glutathione-containing aqueous solution is converted into the reduced glutathione-containing aqueous solution.
- An example is a method of crystallization. Stirring may be involved when concentrating and crystallizing.
- the method for concentrating the reduced glutathione-containing aqueous solution is not particularly limited, and examples thereof include evaporation under reduced pressure conditions and a method using a reverse osmosis membrane.
- the concentration of reduced glutathione in the reduced glutathione-containing aqueous solution when crystallizing reduced glutathione is usually 100 g / L or higher, preferably 250 g / L or higher, more preferably 400 g / L or higher. .
- a method for allowing the reduced glutathione crystals to exist in the reduced glutathione-containing aqueous solution for example, before concentrating the reduced glutathione-containing aqueous solution to crystallize the reduced glutathione crystals, A method may be mentioned in which a crystal of reduced glutathione is added as a seed crystal to cause crystallization so that the concentration of is usually 0.05 to 25 g / L, preferably 0.1 to 10 g / L. Stirring may be involved in adding the seed crystal to cause crystallization.
- the temperature at which the crystal of reduced glutathione is crystallized is usually 0 to 50 ° C., preferably 5 to 40 ° C., more preferably 10 to 30 ° C.
- reduced glutathione crystals By adding a supersaturated reduced glutathione-containing aqueous solution continuously or divided into an aqueous solution in which reduced glutathione crystals are present, reduced glutathione crystals can be precipitated and / or grown.
- Precipitating and / or growing reduced glutathione crystals means adding a supersaturated reduced glutathione-containing aqueous solution to 1) newly crystallize reduced glutathione crystals in the reduced glutathione-containing aqueous solution. 2) increasing the crystallized crystals, and 3) increasing the crystals of reduced glutathione present in the reduced glutathione-containing aqueous solution before adding the supersaturated reduced glutathione-containing aqueous solution. Contains.
- the supersaturated reduced glutathione-containing aqueous solution can be prepared by the same method as described above.
- the temperature at which the supersaturated reduced glutathione-containing aqueous solution is added is not particularly limited as long as the reduced glutathione does not decompose, but is usually 0 to 50 ° C., preferably 5 to 40 ° C., more preferably 10 -30 ° C can be mentioned.
- the supersaturated reduced glutathione-containing aqueous solution may be added continuously at a constant rate, or the total amount of the solution may be divided and added.
- the supersaturated reduced glutathione-containing aqueous solution When the supersaturated reduced glutathione-containing aqueous solution is added in portions, the supersaturated reduced glutathione-containing aqueous solution can be added in an arbitrary number of times, and each addition can be spaced at an arbitrary interval. it can. Further, when the supersaturated reduced glutathione-containing aqueous solution is not added, only stirring may be continued.
- the time required for adding the supersaturated reduced glutathione-containing aqueous solution is usually 4 to 50 hours, preferably 7 to 40 hours, more preferably 10 to 30 hours.
- the amount of the supersaturated reduced glutathione-containing aqueous solution to be added is usually 2 to 200 times equivalent, preferably 5 to 100 times equivalent to the reduced glutathione-containing aqueous solution obtained by crystallization of reduced glutathione crystals. More preferably, an equivalent amount of 8 to 50 times can be mentioned.
- Precipitation and / or growth of glutathione crystals can be promoted by adding a reduced glutathione-containing aqueous solution and then cooling.
- a cooling temperature it is 40 degrees C or less normally, Preferably it is 30 degrees C or less, More preferably, 20 degrees C or less can be mentioned.
- a solvent selected from the group consisting of alcohols and ketones is added or dropped as necessary to promote precipitation and / or growth of reduced glutathione crystals. You can also
- a solution in which alcohols or ketones and water are mixed at an arbitrary ratio can also be used.
- alcohols preferably C1-C6 alcohols, more preferably C1-C3 alcohols, and still more preferably alcohols selected from the group consisting of methanol, ethanol, n-propanol and isopropyl alcohol, Most preferably, alcohols selected from the group consisting of methanol and ethanol can be mentioned.
- the ketones are preferably ketones selected from acetone, methyl ethyl ketone and diethyl ketone, more preferably acetone.
- the temperature at which alcohols and ketones are added or dropped may be any temperature as long as the reduced glutathione does not decompose, but in order to reduce the solubility and improve the crystallinity of the reduced glutathione crystals.
- 40 ° C. or lower preferably 30 ° C. or lower, more preferably 25 ° C. or lower, and most preferably 20 ° C. or lower.
- 0 degreeC or more normally, Preferably 5 degreeC or more can be mentioned.
- the amount of alcohols and ketones to be added or dripped is usually 0.1 to 3 times, preferably 0.2 to 2 times the amount of the aqueous solution.
- the aqueous solution containing the further grown crystals is usually 1 to 48 hours, preferably 1 to 24 hours, most preferably 1 to 12 hours, Usually, the crystals can be aged by stirring or leaving at 0 to 40 ° C., preferably 5 to 30 ° C., more preferably 5 to 20 ° C.
- Aging refers to stopping the process of precipitating reduced glutathione crystals and further growing the crystals.
- Crystal ripening is performed mainly for the purpose of growing a crystal, but a new crystal may be precipitated simultaneously with the growth of the crystal.
- the step of precipitating and / or growing the crystal of reduced glutathione may be resumed.
- Examples of a method for collecting the crystal of reduced glutathione obtained by precipitation and / or growth as described above or an aqueous solution containing the crystal of reduced glutathione obtained by further aging include, for example, filtration, pressurization, and the like. Examples thereof include filtration, suction filtration, and centrifugal separation. Further, in order to reduce the adhesion of the mother liquor to the crystal and improve the quality of the crystal, the crystal may be appropriately washed after collecting the crystal.
- solution used for washing water, methanol, ethanol, acetone, n-propanol, isopropyl alcohol, and one kind of solution selected from them, or a solution in which a plurality of kinds are mixed in any ratio can be used.
- the wet crystals obtained above may be dried.
- the drying conditions may be any method as long as the reduced glutathione crystals can be maintained, and examples thereof include reduced-pressure drying, vacuum drying, fluidized bed drying, and ventilation drying.
- the drying temperature may be any as long as it can remove adhering moisture and solution and the reduced glutathione does not decompose, but it is usually 70 ° C. or lower, preferably 60 ° C. or lower, more preferably 50 ° C. or lower.
- the reduced glutathione crystal of the present invention obtained by the above method can be further pulverized to produce the reduced glutathione crystal of the present invention.
- Crystal crushing can be performed, for example, using an Osterizer Oster Vintage Blender 16-speed dual range (Osterizer OSTER) under the following conditions.
- Example 1 Production of crystal of the present invention-1
- an aqueous solution containing reduced glutathione at a concentration of 125 g / L was obtained.
- the aqueous solution was concentrated to 530 g / L under heating and reduced pressure.
- 0.02 g of ⁇ -type crystals of reduced glutathione (manufactured by Kojin Co., Ltd.) was added as seed crystals to 180 mL of the concentrated solution at 25 ° C., and stirred to crystallize ⁇ -type crystals of reduced glutathione. .
- aqueous solution 3850 mL of a reduced glutathione-containing aqueous solution concentrated to 520 to 530 g / L was added at 25 ° C. over 17 hours to precipitate and / or grow crystals.
- the obtained aqueous solution containing ⁇ -form crystals of reduced glutathione was cooled to 10 ° C., 0.3 times the equivalent amount of ethanol was added, and then the aqueous solution layer was removed by centrifugation to obtain the reduced form
- the ⁇ -form crystals of glutathione were washed with 30 v / v% ethanol and dried by blowing air at 40 ° C. to obtain ⁇ -form crystals of reduced glutathione.
- Example 2 Production of crystal of the present invention-2 A reduced glutathione-containing aqueous solution obtained in the same manner as in Example 1 was concentrated to 436 g / L under heating and reduced pressure. Addition of 0.02 g of ⁇ -type crystals of reduced glutathione (made by Kojin Co., Ltd.) as seed crystals to 330 mL of the concentrated solution at 25 ° C. and stirring to form ⁇ -type crystals of reduced glutathione I let you. To this aqueous solution, 2920 mL of a reduced glutathione aqueous solution concentrated to 420 to 430 g / L was added at 25 ° C. over 11 hours to precipitate and / or grow crystals.
- the resulting reduced glutathione aqueous solution containing ⁇ -form crystals is cooled to 10 ° C., 0.3 times the equivalent amount of ethanol is added, and then the aqueous solution layer is removed by centrifugation to obtain the reduced glutathione obtained
- the ⁇ -form crystal was washed with 30 v / v% ethanol and dried by blowing air at 40 ° C. to obtain ⁇ -form crystal of reduced glutathione.
- Example 3 Production of crystal of the present invention-3 A reduced glutathione-containing solution containing reduced glutathione at a concentration of 134 g / L was prepared in the same manner as in Example 1, and then concentrated to 540 g / L under heating and reduced pressure. 0.02 g of glutathione ⁇ -type crystals (manufactured by Kojin Co., Ltd.) were added as seed crystals to 190 mL of the concentrated liquid at 25 ° C., and stirred to crystallize ⁇ -type crystals of reduced glutathione. .
- aqueous solution 3920 mL of a reduced glutathione aqueous solution concentrated to 540 to 550 g / L was added at 25 ° C. over 15 hours to precipitate and / or grow crystals.
- the obtained aqueous solution containing ⁇ -form crystals of reduced glutathione was cooled to 10 ° C., 0.3 times the equivalent amount of ethanol was added, and then the aqueous solution layer was removed by centrifugation to obtain the reduced form
- the ⁇ -form crystals of glutathione were washed with 30 v / v% ethanol and dried under reduced pressure at room temperature using a box can to obtain ⁇ -form crystals of reduced glutathione.
- the obtained aqueous solution containing ⁇ -form crystals of reduced glutathione was cooled to 10 ° C., 0.3 times the equivalent amount of ethanol was added, and then the aqueous solution layer was removed by centrifugation to obtain the reduced form
- the ⁇ -form crystals of glutathione were washed with 60 v / v% ethanol and dried under reduced pressure at 40 ° C. to obtain ⁇ -form crystals of reduced glutathione.
- Example 4 Measurement of powder physical properties ⁇ -type crystals of reduced glutathione obtained in Examples 1 to 3, ⁇ -type crystals of reduced glutathione obtained in Comparative Examples, and ⁇ -type crystals of commercially available reduced glutathione For (commercial products A and B), the average length L, the average width W, the ratio L / W of the average length L and the average width W, the crude specific volume and the dense specific volume were measured. The results are shown in Table 1.
- the ⁇ -type crystals of reduced glutathione obtained in Examples 1 to 3 were crystals compared to the ⁇ -type crystals of reduced glutathione obtained in Comparative Example and the commercial product A. It was found that the average thickness T was large and the grindability was excellent.
- Example 5 Production of crystal of the present invention-4 The ⁇ -type crystals of reduced glutathione obtained in Example 3 and Comparative Example were pulverized, and the change in the crude specific volume over time was measured.
- Example 3 Further, the crude specific volume of the ⁇ -type crystals of reduced glutathione obtained in Example 3 was smaller than the crude specific volume of the ⁇ -type crystals of reduced glutathione obtained in the comparative example at any pulverization time. .
- Example 3 As shown in Table 3, the ⁇ -type crystals of reduced glutathione obtained in Example 3 were compared with the ⁇ -type crystals of reduced glutathione obtained in Comparative Example both before and after pulverization. Since the repose angle and the collapse angle were small, it was found that the fluidity was good and the powder physical properties were excellent.
- the crystal of the present invention was superior in pulverization and powder physical properties to existing reduced glutathione crystals.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Metallurgy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
(1)結晶の平均厚みが10μm以上である、還元型グルタチオンの結晶。
(2)結晶の平均長Lと、平均幅Wの比L/Wが、6.0以下である、(1)に記載の結晶。
(3)粗比容が2.5mL/g以下である、(1)又は(2)記載の結晶。
(4)密比容が2.0mL/g以下である、(1)~(3)のいずれか1に記載の結晶。
(5)安息角が50度以下である、(1)~(4)のいずれか1に記載の結晶。
(6)崩壊角が45度以下である、(1)~(5)のいずれか1に記載の結晶。
(7)還元型グルタチオンの結晶がα晶である、(1)~(6)のいずれか1に記載の結晶。
(8)還元型グルタチオン含有水溶液中に還元型グルタチオンの結晶を存在せしめた後、該水溶液に、過飽和状態の還元型グルタチオン含有水溶液を連続又は分割しながら添加することにより、還元型グルタチオンの結晶を析出及び/又は成長させ、その後、該水溶液中に含有される還元型グルタチオンの結晶を採取することを特徴とする、還元型グルタチオンの結晶の製造方法。
(9)さらに、採取した還元型グルタチオンの結晶を粉砕する工程を含む、(8)に記載の製造方法。
(10)還元型グルタチオンの結晶がα晶である、(8)又は(9)に記載の製造方法。
本明細書においては、顕微鏡を用いて結晶を3次元で把握したときに、最も長い軸を縦軸といい、縦軸に垂直な軸を横軸という(図2)。さらに、結晶の縦軸方向の長さ、横軸の断面の長径、横軸の断面の短径を、それぞれ、「結晶の長さ」、「結晶の幅」、及び「結晶の厚み」といい(図2参照)、それぞれの平均を、「平均長」、「平均幅」、「平均厚み」という。
ふるい:1.4mm
スペーサ:30mm
振動幅:0.6~0.7mm
結晶容量:40mL
タッピング速度:1回/秒
タッピング回数:200回
安息角テーブルに振動を与えないように回転して、3ヶ所で角度を読み、それらの相加平均値を安息角とする。
ふるい:1.4mm
振動幅:0.6~0.7mm
安息角テーブルユニット(部品番号:MT-1028)使用
安息角テーブルユニットの下についている鍾をゆっくりタッピングテーブルの下まで持ち上げて落下させる操作を3回繰り返す。上記安息角の測定方法と同様の方法で、3ヶ所の角度を読み、それらの相加平均値を崩壊角とする。
本発明の製造方法は、還元型グルタチオン含有水溶液中に還元型グルタチオン結晶を存在せしめた後、該水溶液に過飽和状態の還元型グルタチオン含有水溶液を連続又は分割しながら添加することにより、還元型グルタチオンの結晶を析出及び/又は成長させ、その後、該水溶液中に含有される還元型グルタチオンの結晶を採取することを特徴とする方法である。
回転数:33700~33900r/min
直径:50mm
サンプル投入量:20g/回
本発明の結晶の製造-1
日本国特許第5243963号明細書の実施例1に記載された方法に従い、還元型グルタチオンを125g/Lの濃度で含む水溶液を得た。当該水溶液を加熱減圧下で530g/Lまで濃縮した。25℃の該濃縮液180mLに、種晶として還元型グルタチオンのα型の結晶0.02g(興人社製)添加し、撹拌することで、還元型グルタチオンのα型の結晶を起晶させた。
本発明の結晶の製造-2
実施例1と同様の方法で得た還元型グルタチオン含有水溶液を加熱減圧下で436g/Lまで濃縮した。25℃の該濃縮液330mLに対し、種晶として還元型グルタチオンのα型の結晶0.02g(興人社製)を添加し、撹拌することで、還元型グルタチオンのα型の結晶を起晶させた。該水溶液に、420~430g/Lに濃縮した還元型グルタチオン水溶液2920mLを25℃で11時間かけて添加し、結晶を析出及び/又は成長させた。
本発明の結晶の製造-3
実施例1と同様の方法で還元型グルタチオンを134g/Lの濃度で含む還元型グルタチオン含有溶液を調整した後、加熱減圧下で540g/Lまで濃縮した。25℃の該濃縮液190mLに対し、種晶としてグルタチオンのα型の結晶0.02g(興人社製)を添加し、撹拌することで、還元型グルタチオンのα型の結晶を起晶させた。
日本国特許第5243963号明細書の実施例1に記載された方法に従い、還元型グルタチオンを179g/Lの濃度で含む水溶液を得た。当該水溶液を加熱減圧下で546g/Lまで濃縮した。25℃の該濃縮液950mLに対し、種晶として還元型グルタチオンのα型の結晶0.05g(興人社製)を添加した。種晶添加後、25℃で10時間撹拌し、還元型グルタチオンのα型の結晶を起晶させた。
粉体物性の測定
実施例1~3で取得された還元型グルタチオンのα型の結晶、比較例で取得された還元型グルタチオンのα型の結晶、及び市販品の還元型グルタチオンのα型の結晶(市販品A及びB)について、結晶の平均長L、平均幅W、平均長Lと平均幅Wの比L/W、粗比容及び密比容を測定した。結果を表1に示す。
本発明の結晶の製造-4
実施例3及び比較例で得られた還元型グルタチオンのα型の結晶を粉砕し、経時の粗比容の変化を測定した。
Claims (10)
- 結晶の平均厚みが10μm以上である、還元型グルタチオンの結晶。
- 結晶の平均長Lと、平均幅Wの比L/Wが、6.0以下である、請求項1に記載の結晶。
- 粗比容が2.5mL/g以下である、請求項1又は2記載の結晶。
- 密比容が2.0mL/g以下である、請求項1~3のいずれか1項に記載の結晶。
- 安息角が50度以下である、請求項1~4のいずれか1項に記載の結晶。
- 崩壊角が45度以下である、請求項1~5のいずれか1項に記載の結晶。
- 還元型グルタチオンの結晶がα晶である、請求項1~6のいずれか1項に記載の結晶。
- 還元型グルタチオン含有水溶液中に還元型グルタチオンの結晶を存在せしめた後、該水溶液に、過飽和状態の還元型グルタチオン含有水溶液を連続又は分割しながら添加することにより、還元型グルタチオンの結晶を析出及び/又は成長させ、その後、該水溶液中に含有される還元型グルタチオンの結晶を採取することを特徴とする、還元型グルタチオンの結晶の製造方法。
- さらに、採取した還元型グルタチオンの結晶を粉砕する工程を含む、請求項8に記載の製造方法。
- 還元型グルタチオンの結晶がα晶である、請求項8又は9に記載の製造方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020187026716A KR102406826B1 (ko) | 2016-03-17 | 2017-03-10 | 환원형 글루타티온의 결정 및 그 제조 방법 |
CN201780017549.3A CN108884129B (zh) | 2016-03-17 | 2017-03-10 | 还原型谷胱甘肽的晶体及其制造方法 |
US16/083,483 US10774109B2 (en) | 2016-03-17 | 2017-03-10 | Crystal of reduced glutathione and method for producing same |
JP2018505888A JP6978405B2 (ja) | 2016-03-17 | 2017-03-10 | 還元型グルタチオンの結晶及びその製造方法 |
EP17766554.4A EP3431487B1 (en) | 2016-03-17 | 2017-03-10 | Crystal of reduced glutathione and method for producing same |
CN202310689790.8A CN116640180A (zh) | 2016-03-17 | 2017-03-10 | 还原型谷胱甘肽的晶体及其制造方法 |
US16/988,335 US20200369721A1 (en) | 2016-03-17 | 2020-08-07 | Crystal of reduced glutathione and method for producing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016053843 | 2016-03-17 | ||
JP2016-053843 | 2016-03-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/083,483 A-371-Of-International US10774109B2 (en) | 2016-03-17 | 2017-03-10 | Crystal of reduced glutathione and method for producing same |
US16/988,335 Division US20200369721A1 (en) | 2016-03-17 | 2020-08-07 | Crystal of reduced glutathione and method for producing same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017159554A1 true WO2017159554A1 (ja) | 2017-09-21 |
Family
ID=59850340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/009655 WO2017159554A1 (ja) | 2016-03-17 | 2017-03-10 | 還元型グルタチオンの結晶及びその製造方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US10774109B2 (ja) |
EP (1) | EP3431487B1 (ja) |
JP (1) | JP6978405B2 (ja) |
KR (1) | KR102406826B1 (ja) |
CN (2) | CN116640180A (ja) |
WO (1) | WO2017159554A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2990048B1 (en) * | 2013-01-21 | 2023-03-01 | Kyowa Hakko Bio Co., Ltd. | Nitric oxide concentration elevating agent |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008047792A1 (fr) * | 2006-10-16 | 2008-04-24 | Kyowa Hakko Bio Co., Ltd. | Cristal de glutathione et son procédé de fabrication |
WO2014192546A1 (ja) * | 2013-05-28 | 2014-12-04 | アサヒグループホールディングス株式会社 | 選択的発酵方法による粗糖及びエタノールの製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3750395A (en) | 1971-10-22 | 1973-08-07 | Westinghouse Electric Corp | Overspeed protection system for a turbo-generator unit |
CN102803567B (zh) * | 2009-06-03 | 2015-06-03 | 协和发酵生化株式会社 | 制造还原型谷胱甘肽的方法 |
-
2017
- 2017-03-10 CN CN202310689790.8A patent/CN116640180A/zh active Pending
- 2017-03-10 WO PCT/JP2017/009655 patent/WO2017159554A1/ja active Application Filing
- 2017-03-10 CN CN201780017549.3A patent/CN108884129B/zh active Active
- 2017-03-10 JP JP2018505888A patent/JP6978405B2/ja active Active
- 2017-03-10 US US16/083,483 patent/US10774109B2/en active Active
- 2017-03-10 KR KR1020187026716A patent/KR102406826B1/ko active IP Right Grant
- 2017-03-10 EP EP17766554.4A patent/EP3431487B1/en active Active
-
2020
- 2020-08-07 US US16/988,335 patent/US20200369721A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008047792A1 (fr) * | 2006-10-16 | 2008-04-24 | Kyowa Hakko Bio Co., Ltd. | Cristal de glutathione et son procédé de fabrication |
WO2014192546A1 (ja) * | 2013-05-28 | 2014-12-04 | アサヒグループホールディングス株式会社 | 選択的発酵方法による粗糖及びエタノールの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2017159554A1 (ja) | 2019-01-24 |
US20190085023A1 (en) | 2019-03-21 |
JP6978405B2 (ja) | 2021-12-08 |
EP3431487A1 (en) | 2019-01-23 |
US20200369721A1 (en) | 2020-11-26 |
US10774109B2 (en) | 2020-09-15 |
CN108884129A (zh) | 2018-11-23 |
EP3431487A4 (en) | 2019-10-30 |
KR102406826B1 (ko) | 2022-06-10 |
KR20180127346A (ko) | 2018-11-28 |
EP3431487B1 (en) | 2021-12-01 |
CN108884129B (zh) | 2024-05-03 |
CN116640180A (zh) | 2023-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1070720C (zh) | 从溶液中回收有机化合物的方法 | |
JP5536449B2 (ja) | レバウディオシドa組成物及びレバウディオシドaを精製するための方法 | |
CN112574263B (zh) | 一种阿洛酮糖结晶的制备方法 | |
US20230159579A1 (en) | Crystallization of allulose under reduced pressure | |
KR20190003308A (ko) | 결정형 기능성 감미료의 제조방법 | |
WO2017159554A1 (ja) | 還元型グルタチオンの結晶及びその製造方法 | |
US20210395788A1 (en) | Purification of magnesium lactate from fermentation broths having high amounts of impurities | |
CN104861014B (zh) | 一种盐酸表阿霉素结晶的制备方法 | |
CN113620794A (zh) | 一种制备大粒度乙基香兰素的结晶方法 | |
JP4530342B2 (ja) | 含蜜糖の製造方法及び製造装置 | |
JP2006020521A5 (ja) | ||
CN113912475B (zh) | 一种赤藓糖醇晶体的制备方法 | |
JP4942902B2 (ja) | 含蜜結晶組成物およびその製造法 | |
WO2018066690A1 (ja) | シチジンジリン酸コリンの結晶及びその製造方法 | |
WO2013039094A1 (ja) | アミノ酸の製造法 | |
CN111410626B (zh) | 赛洛多辛α-晶型的制备方法 | |
EP0971040B1 (fr) | Procédé de fabrication de fructose cristallisé | |
JP2018203690A (ja) | L−カルノシンの結晶及びその製造方法 | |
CN113121376A (zh) | 一种谷氨酸的制备方法 | |
WO2017195743A1 (ja) | 3'-シアリルラクトースナトリウム塩・n水和物の結晶及びその製造方法 | |
WO2022026431A1 (en) | Multistage agitation for the crystallization of spray dried or amorphous solid materials | |
JP2008056574A (ja) | 結晶アスコピロンpの製造法 | |
KR20100116110A (ko) | 캠벨얼리를 이용한 와인향주의 제조방법 | |
JPS60999B2 (ja) | 蔗糖結晶の製造方法 | |
BR102012013327B1 (pt) | cristalização de xilitol em água- etanol utilizando xilitol e sílica (nanoparticulada) pirogênica como semente |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2018505888 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20187026716 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201780017549.3 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017766554 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017766554 Country of ref document: EP Effective date: 20181017 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17766554 Country of ref document: EP Kind code of ref document: A1 |